Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2014-04-09 Regulatory Filings
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter addressed to the SEC regarding a Registration Statement on Form S-3 filed by CopyTele, Inc. It discusses the company's position on whether a particular shareholder (Mars Overseas Limited) is an affiliate under Rule 405 of the Securities Act. The content is focused on regulatory compliance, legal interpretations, and clarifications related to a registration statement filing. There is no indication that this document is a financial report, earnings release, or any other type of corporate filing such as an annual report or interim report. Instead, it is a regulatory correspondence responding to SEC staff comments about a registration statement. Therefore, this document fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2014-04-09 English
Regulatory Filings 2014
Regulatory Filings
2014-04-07 English
FORM S-3/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-3/A registration statement filed with the SEC, which is used for registering securities for public offering. It includes detailed information about the types of securities to be offered, the registration fee, and legal disclaimers. This type of filing is related to capital raising activities and financing, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement itself. Therefore, it fits the category of Capital/Financing Update filings.
2014-03-31 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It contains a detailed description of the company's securities, including common stock and preferred stock, their rights, voting, dividend policies, and other corporate governance provisions. The document does not present financial statements or earnings data, nor is it an announcement of a report publication. It is not a proxy statement, dividend notice, or management change announcement. The Form 8-K is a regulatory filing used to report significant corporate events and disclosures. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2014-03-31 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from CopyTele, Inc. to the SEC responding to an inquiry about their Registration Statement on Form S-3 filed on February 11, 2014. It discusses the computation of non-affiliated stockholders and explains why Mars Overseas Limited is not considered an affiliate. The letter is correspondence related to a regulatory filing and does not contain financial statements or detailed financial performance data. It is not a report itself but a response to SEC staff comments regarding a registration statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2014-03-28 English
PRIMARY DOCUMENT
Director's Dealing
2014-03-24 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.